Florence Ader
Hospices Civils de Lyon
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Florence Ader as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:27 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07849933 · Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIVHospices Civils de Lyon · not yet recruiting · Human Immunodeficiency Virus Infection (HIV) · principal investigator
- N/ANCT05073328 · Burden of Care of Long COVID Patients After Hospital DischargeMikhail Dziadzko, MD, PhD · completed · COVID-19, COVID Long · study chair
- Ph3NCT04315948 · Trial of Treatments for COVID-19 in Hospitalized AdultsInstitut National de la Santé Et de la Recherche Médicale, France · completed · Corona Virus Infection · study chair
- N/ANCT03659773 · Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant RecipientsHospices Civils de Lyon · completed · Vaccination, Hematopoietic Stem Cells · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:27 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 1,945 citationsRCR 122.3
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.Lancet Infect Dis · 2022265 citationsRCR 17.7
- Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.Am J Hematol · 2020122 citationsRCR 4.6
- An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.Clin Microbiol Infect · 202190 citationsRCR 4.7
- Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.J Antimicrob Chemother · 202237 citationsRCR 2.1
- 33 citationsRCR 2.7
- Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.BMC Infect Dis · 201619 citationsRCR 1.1
- Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.Antimicrob Agents Chemother · 202116 citationsRCR 0.6
- Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.Clin Infect Dis · 202410 citationsRCR 1.5
- An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.Clin Microbiol Infect · 20228 citationsRCR 0.6